Currently, the X1 is approved for use in conventional stereotactic body radiotherapy, intensity-modulated radiation therapy, and stereotactic radiosurgery. RefleXion is also developing biology-guided radiotherapy (BgRT) for the system, which uses PET/CT to direct treatment photons to cancer sites; BgRT is currently limited to investigational use in the U.S. until it receives U.S. Food and Drug Administration approval.

Installation at the Center for Cancer and Blood Disorders is expected to begin in early 2022, according to the company.